Equities

Microbot Medical Inc

Microbot Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.98
  • Today's Change-0.49 / -8.96%
  • Shares traded15.06k
  • 1 Year change-31.22%
  • Beta3.4596
Data delayed at least 15 minutes, as of Sep 23 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-clinical medical device company. It specializes in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms include ViRob, TipCAT, LIBERTY and certain CardioSert assets. The ViRob is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The TipCAT is a disposable self-propelled locomotive device that is specially designed to advance tubular anatomy. LIBERTY is designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body's vasculature. It is developing Self-Cleaning Shunt (SCSTM), for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH) using ViRob platform. It is developing the fully disposable robot for various endovascular interventional procedures using LIBERTY and CardioSert platforms. It is also focused on the development of a multi generation pipeline portfolio.

  • Revenue in USD (TTM)0.00
  • Net income in USD-13.12m
  • Incorporated1988
  • Employees17.00
  • Location
    Microbot Medical Inc25 RECREATION PARK DR SUITE 108HINGHAM 02043United StatesUSA
  • Phone+1 (908) 938-5561
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regen BioPharma Inc235.87k1.14m33.89m1.00------143.68-0.0005-0.00050.00005-0.00170.2222--0.9809235,870.00107.08-771.89--------482.00-2,749.25--------55.6311.35-347.67------
Comera Life Sciences Holdings Inc242.06k-9.00m34.36m9.00------141.94-1.36-1.360.02370.16020.0043-------15.44---15.79--59.08---3,634.83------0.00------242.87------
Corvus Pharmaceuticals Inc0.00-36.57m34.44m28.00--0.4285-----0.7989-0.79890.001.730.00----0.00-36.22-39.16-40.76-43.08-----------4.440.00-------621.28---70.40--
Acurx Pharmaceuticals Inc0.00-12.56m34.61m3.00--3.54-----1.23-1.230.000.8560.00----0.00-94.08---103.34--------------0.00-------177.12------
Syros Pharmaceuticals Inc25.24m-109.47m35.09m124.00--1.13--1.39-17.31-17.313.994.920.1403--11.30203,564.50-60.82-52.85-74.62-62.36-----433.67-828.85----0.5684--55.62136.57-3.00---11.72--
Adamis Pharmaceuticals Corp734.47k-31.57m35.28m15.00--5.01--48.03-0.205-0.26180.0050.0470.0184.121.1248,964.67-77.56-67.59-108.43-91.72-632.9716.94-4,297.89-277.051.53--0.00---20.45-19.353.48--58.81--
Elite Pharmaceuticals Inc32.88m6.82m35.32m43.005.181.384.411.070.00670.00670.03250.02530.84192.478.96764,610.0017.45-1.4621.22-1.8846.2345.7220.72-2.283.4399.190.3482--27.1127.3374.87-18.35-14.71--
AcelRx Pharmaceuticals Inc2.88m45.70m35.36m43.000.83261.070.744112.290.28830.28830.02130.2250.04242.9412.2966,883.7267.34-43.6688.87-52.59-15.89-51.081,588.91-935.081.76-21.970.2298---47.97-30.4813.08---13.26--
Microbot Medical Inc0.00-13.12m35.40m17.00--4.15-----1.85-1.850.001.200.00----0.00-80.95-47.00-88.99-54.77------------0.00-------23.38--22.51--
Maia Biotechnology Inc0.00-14.77m35.54m----4.11-----1.48-1.480.000.7916---------------------------18.820.00-------88.41------
CASI Pharmaceuticals Inc34.91m-32.10m35.65m168.00--0.5325--1.02-2.32-2.322.524.920.2653.144.36207,767.90-23.77-35.38-32.14-43.3358.39---89.69-337.702.77--0.0111--99.25--24.09--133.52--
Aikido Pharma Inc0.00-14.58m35.94m4.00--0.3919-----2.77-2.770.0017.480.00----0.00-10.88-20.89-10.99-22.22-------1,985.08---153.900.00------41.87--173.93--
Cyclerion Therapeutics Inc1.90m-48.43m36.57m32.00--1.44--19.27-1.12-1.120.04370.58330.0342--16.7259,312.50-87.31-133.29-106.93-172.00-----2,551.69-4,296.24----0.00--71.69--33.62---65.56--
Lisata Therapeutics Inc0.00-24.57m36.68m27.00--0.2299-----6.13-6.130.0020.400.00----0.00-25.27-35.43-26.17-43.42------------0.00-------237.01---44.10--
Mannatech, Inc.146.30m6.35m36.78m246.006.201.744.750.25143.103.1071.3411.082.392.32661.99594,711.4010.364.1322.457.8878.2679.084.341.670.8758301.760.024856.855.52-2.3957.20---22.2423.56
Data as of Sep 23 2022. Currency figures normalised to Microbot Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

10.83%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2022266.82k3.75%
BlackRock Fund Advisorsas of 30 Jun 2022151.03k2.13%
Contego Capital Group, Inc.as of 30 Jun 2022100.00k1.41%
Dimensional Fund Advisors LPas of 30 Jun 202288.84k1.25%
Geode Capital Management LLCas of 30 Jun 202251.82k0.73%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 202237.19k0.52%
SSgA Funds Management, Inc.as of 30 Jun 202226.07k0.37%
Renaissance Technologies LLCas of 30 Jun 202220.10k0.28%
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 202215.50k0.22%
Cetera Advisor Networks LLCas of 30 Jun 202212.55k0.18%
More ▼
Data from 30 Jun 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.